BR112017003571A2 - terapia combinada - Google Patents
terapia combinadaInfo
- Publication number
- BR112017003571A2 BR112017003571A2 BR112017003571A BR112017003571A BR112017003571A2 BR 112017003571 A2 BR112017003571 A2 BR 112017003571A2 BR 112017003571 A BR112017003571 A BR 112017003571A BR 112017003571 A BR112017003571 A BR 112017003571A BR 112017003571 A2 BR112017003571 A2 BR 112017003571A2
- Authority
- BR
- Brazil
- Prior art keywords
- combination therapy
- effective amount
- combination
- cognitive
- administering
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 230000001149 cognitive effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Massaging Devices (AREA)
Abstract
a presente invenção provê um método de tratar uma doença cognitiva ou neurodegenerativa, compreendendo administrar a um paciente em necessidade de tal tratamento uma quantidade eficaz de um composto da fórmula: , ou um sal farmaceuticamente aceitável dos mesmos; em combinação com uma quantidade eficaz de um anticorpo monoclonal anti-n3pglu abeta.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462050967P | 2014-09-16 | 2014-09-16 | |
| PCT/US2015/048807 WO2016043997A1 (en) | 2014-09-16 | 2015-09-08 | Combination alzheimer therapy using anti-n3pglu abeta antibodies + a bace inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017003571A2 true BR112017003571A2 (pt) | 2017-12-19 |
Family
ID=54207720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017003571A BR112017003571A2 (pt) | 2014-09-16 | 2015-09-08 | terapia combinada |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US9999624B2 (pt) |
| EP (1) | EP3193882A1 (pt) |
| JP (1) | JP6339741B2 (pt) |
| KR (1) | KR101871128B1 (pt) |
| CN (1) | CN106687136A (pt) |
| AP (1) | AP2017009794A0 (pt) |
| AR (1) | AR101740A1 (pt) |
| AU (1) | AU2015318257B2 (pt) |
| BR (1) | BR112017003571A2 (pt) |
| CA (1) | CA2956835A1 (pt) |
| CL (1) | CL2017000558A1 (pt) |
| CO (1) | CO2017001875A2 (pt) |
| CR (1) | CR20170080A (pt) |
| DO (1) | DOP2017000071A (pt) |
| EA (1) | EA031764B1 (pt) |
| EC (1) | ECSP17015977A (pt) |
| IL (1) | IL250387A0 (pt) |
| MX (1) | MX2017003414A (pt) |
| NZ (1) | NZ728636A (pt) |
| PE (1) | PE20170464A1 (pt) |
| PH (1) | PH12017500493A1 (pt) |
| SG (1) | SG11201701330PA (pt) |
| SV (1) | SV2017005389A (pt) |
| TN (1) | TN2017000072A1 (pt) |
| TW (1) | TWI599358B (pt) |
| WO (1) | WO2016043997A1 (pt) |
| ZA (1) | ZA201700826B (pt) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR107893A1 (es) * | 2016-03-15 | 2018-06-28 | Astrazeneca Ab | TERAPIAS COMBINADAS, COMBINACIÓN DE UN INHIBIDOR DE BACE Y UN ANTICUERPO O UN FRAGMENTO DE UNIÓN AL ANTÍGENO PARA EL TRATAMIENTO DE UN TRASTORNO ASOCIADO CON LA ACUMULACIÓN DE b AMILOIDE |
| TWI798751B (zh) | 2016-07-01 | 2023-04-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| US10034861B2 (en) | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| EP3500296A1 (en) * | 2016-08-18 | 2019-06-26 | Eli Lilly and Company | Combination therapy of bace-1 inhibitor and anti-n3pglu abeta antibody |
| TWI669119B (zh) * | 2016-10-21 | 2019-08-21 | 美國禮來大藥廠 | 組合療法 |
| CN109803653A (zh) | 2016-10-28 | 2019-05-24 | H.隆德贝克有限公司 | 包括给予咪唑并吡嗪酮的组合治疗 |
| JOP20190247A1 (ar) * | 2017-04-20 | 2019-10-20 | Lilly Co Eli | أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها |
| JP7368856B2 (ja) | 2017-07-25 | 2023-10-25 | トゥルーバインディング，インコーポレイテッド | Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療 |
| ES2899868T3 (es) | 2017-12-14 | 2022-03-15 | H Lundbeck As | Tratamientos de combinación que comprenden la administración de 1H-pirazolo[4,3-b]piridinas |
| AR113926A1 (es) | 2017-12-14 | 2020-07-01 | H Lundbeck As | Derivados de 1h-pirazolo[4,3-b]piridinas |
| CN111511742B (zh) | 2017-12-20 | 2023-10-27 | H.隆德贝克有限公司 | 作为PDE1抑制剂的吡唑并[4,3-b]吡啶和咪唑并[1,5-a]嘧啶 |
| US10350226B1 (en) | 2018-06-27 | 2019-07-16 | Joshua O. Atiba | Therapy and prevention of prion protein complex infections |
| US12350278B2 (en) | 2018-06-27 | 2025-07-08 | Joshua O. Atiba | Therapy and prevention of prion protein complex infections in non-human animals |
| EP4138888A1 (en) * | 2020-04-23 | 2023-03-01 | Eli Lilly and Company | Subcutaneous absorption and bioavailability of antibodies |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| AU2023314807A1 (en) | 2022-07-29 | 2025-03-06 | Alector Llc | Transferrin receptor antigen-binding domains and uses therefor |
| WO2024026471A1 (en) | 2022-07-29 | 2024-02-01 | Alector Llc | Cd98hc antigen-binding domains and uses therefor |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE424383T1 (de) | 2003-08-08 | 2009-03-15 | Schering Corp | Cyclische amine mit benzamidsubstituent als bace- 1-inhibitoren |
| RS54311B1 (en) | 2008-01-18 | 2016-02-29 | Eisai R&D Management Co. Ltd. | KONDEZOVANI AMINODIHYDROTIAZINE DERIVATIVE |
| ES2764728T3 (es) | 2010-08-12 | 2020-06-04 | Lilly Co Eli | Anticuerpos anti péptido Beta Amiloide N3pGlu y usos de los mismos |
| GB201101140D0 (en) | 2011-01-21 | 2011-03-09 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
| TWI593692B (zh) * | 2013-03-12 | 2017-08-01 | 美國禮來大藥廠 | 四氫吡咯并噻嗪化合物 |
-
2015
- 2015-09-01 TW TW104128851A patent/TWI599358B/zh not_active IP Right Cessation
- 2015-09-02 AR ARP150102803A patent/AR101740A1/es unknown
- 2015-09-08 JP JP2017514623A patent/JP6339741B2/ja not_active Expired - Fee Related
- 2015-09-08 AU AU2015318257A patent/AU2015318257B2/en not_active Ceased
- 2015-09-08 EP EP15771800.8A patent/EP3193882A1/en not_active Withdrawn
- 2015-09-08 CA CA2956835A patent/CA2956835A1/en not_active Abandoned
- 2015-09-08 EA EA201790305A patent/EA031764B1/ru not_active IP Right Cessation
- 2015-09-08 WO PCT/US2015/048807 patent/WO2016043997A1/en active Application Filing
- 2015-09-08 SG SG11201701330PA patent/SG11201701330PA/en unknown
- 2015-09-08 CR CR20170080A patent/CR20170080A/es unknown
- 2015-09-08 US US15/503,027 patent/US9999624B2/en not_active Expired - Fee Related
- 2015-09-08 NZ NZ728636A patent/NZ728636A/en not_active IP Right Cessation
- 2015-09-08 PE PE2017000406A patent/PE20170464A1/es unknown
- 2015-09-08 CN CN201580049574.0A patent/CN106687136A/zh active Pending
- 2015-09-08 KR KR1020177006748A patent/KR101871128B1/ko not_active Expired - Fee Related
- 2015-09-08 AP AP2017009794A patent/AP2017009794A0/en unknown
- 2015-09-08 MX MX2017003414A patent/MX2017003414A/es unknown
- 2015-09-08 TN TN2017000072A patent/TN2017000072A1/en unknown
- 2015-09-08 BR BR112017003571A patent/BR112017003571A2/pt not_active Application Discontinuation
-
2017
- 2017-02-01 IL IL250387A patent/IL250387A0/en unknown
- 2017-02-02 ZA ZA2017/00826A patent/ZA201700826B/en unknown
- 2017-02-22 SV SV2017005389A patent/SV2017005389A/es unknown
- 2017-02-24 CO CONC2017/0001875A patent/CO2017001875A2/es unknown
- 2017-03-08 CL CL2017000558A patent/CL2017000558A1/es unknown
- 2017-03-14 DO DO2017000071A patent/DOP2017000071A/es unknown
- 2017-03-15 EC ECIEPI201715977A patent/ECSP17015977A/es unknown
- 2017-03-15 PH PH12017500493A patent/PH12017500493A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AP2017009794A0 (en) | 2017-03-31 |
| TN2017000072A1 (en) | 2018-07-04 |
| PE20170464A1 (es) | 2017-04-26 |
| AU2015318257B2 (en) | 2018-06-14 |
| US20170224702A1 (en) | 2017-08-10 |
| ECSP17015977A (es) | 2018-03-31 |
| ZA201700826B (en) | 2018-12-19 |
| EP3193882A1 (en) | 2017-07-26 |
| KR20170036103A (ko) | 2017-03-31 |
| CO2017001875A2 (es) | 2017-05-19 |
| WO2016043997A1 (en) | 2016-03-24 |
| SV2017005389A (es) | 2018-01-17 |
| JP6339741B2 (ja) | 2018-06-06 |
| JP2017529348A (ja) | 2017-10-05 |
| EA201790305A1 (ru) | 2017-07-31 |
| DOP2017000071A (es) | 2017-06-15 |
| CN106687136A (zh) | 2017-05-17 |
| CA2956835A1 (en) | 2016-03-24 |
| TWI599358B (zh) | 2017-09-21 |
| EA031764B1 (ru) | 2019-02-28 |
| KR101871128B1 (ko) | 2018-06-25 |
| AR101740A1 (es) | 2017-01-11 |
| PH12017500493A1 (en) | 2017-08-07 |
| CL2017000558A1 (es) | 2017-11-10 |
| TW201618786A (zh) | 2016-06-01 |
| AU2015318257A1 (en) | 2017-02-16 |
| CR20170080A (es) | 2017-03-30 |
| NZ728636A (en) | 2018-05-25 |
| US9999624B2 (en) | 2018-06-19 |
| MX2017003414A (es) | 2017-06-19 |
| IL250387A0 (en) | 2017-03-30 |
| SG11201701330PA (en) | 2017-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017003571A2 (pt) | terapia combinada | |
| BR112018077492A2 (pt) | métodos de tratamento de câncer de ovário | |
| UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
| EA201590655A8 (ru) | Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений | |
| MX2016002645A (es) | Tratamiento combinado para tratar el glioblastoma. | |
| MX2018012493A (es) | Métodos para controlar y tratar el cáncer. | |
| EA201590654A1 (ru) | Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона | |
| EA201491857A1 (ru) | АЛЛОСТЕРИЧЕСКИЕ МОДУЛЯТОРЫ α7 НИКОТИНОВОГО ХОЛИНОРЕЦЕПТОРА, ИХ ПРОИЗВОДНЫЕ И ИХ ПРИМЕНЕНИЕ | |
| EA201591687A1 (ru) | Индукционная терапия ритуксимабом с последующим лечением с использованием глатирамера ацетата | |
| EA201690039A1 (ru) | Ингибиторы rorc2 и способы их применения | |
| EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
| TW201613578A (en) | Pharmaceutical combinations | |
| BR112019005539A2 (pt) | métodos de tratamento de lesão renal aguda | |
| EA201692155A1 (ru) | МОДУЛЯТОРЫ Hsp70 И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ | |
| BR112017002449A2 (pt) | tratamento de sintomas associados com terapia de privação androgênica | |
| BR112018002763A2 (pt) | método para cicatrização de ferimentos | |
| BR112019005217A2 (pt) | terapia combinada | |
| WO2016069477A3 (en) | A method of treating cancer that overexpresses topbp1 | |
| MX2017002093A (es) | Terapia con anticuerpos para vih como sustituto de tratamiento. | |
| EA202190626A2 (ru) | Комбинация тразодона и габапентина для лечения боли | |
| TR201906539T4 (tr) | Mentol, Linalool ve/veya Icilin Kullanarak Beyin Travması ve İnmelerden Kaynaklanan Non-İnflamatuar Nöron Hasarının Tedavisi veya Önlenmesi. | |
| WO2014153505A3 (en) | Treatment of chemotherapy-induced peripheral neuropathy | |
| EA201301340A1 (ru) | Фармацевтическая композиция, обладающая нейропротекторным действием, её применение и способы повышения жизнеспособности и профилактики или лечения цереброваскулярных и нейродегенеративных заболеваний | |
| EA202090453A3 (ru) | Антитела к cd40 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |